Task 4: The Interventional Agent Development Services program

任务 4：介入药物开发服务计划

• 批准号: 9430224
• 负责人: Jon Carl Mirsalis
• 金额: $ 191.89万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-01-26 至 2018-01-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9430224
• 关键词: Categories; Contracts; Development; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; Safety; Services; Toxicology; Translational Research; pathogen; pre-clinical; programs; therapeutic development; therapy development

This contract provides for preclinical microbiological, safety, toxicology and biokenetics services under the NIAID Preclinical Services for the Development of Interventional Agents Program.

该合同规定在 NIAID 介入药物开发临床前服务计划下提供临床前微生物学、安全性、毒理学和生物动力学服务。